Led by Dr. Chetan Bettegowda and Dr. Jordina Rincon-Torroella, our lab uses genetic analysis, biomarkers and patient outcome data to identify better ways to diagnose and treat disease. We research a variety of neurological conditions, including central nervous system tumors, trigeminal neuralgia and traumatic brain and spinal injuries.

Work in the Livia Casciola-Rosen Lab explores the shared mechanisms present in autoimmune rheumatic diseases, specifically scleroderma, Sjogren's syndrome and myositis. We use disease-specific autoantibodies to identify the factors that cause the autoimmune response in such diseases. Our current research involves identifying the antigen targets of autoimmune diseases, investigating the autoantigens targeted in cancers associated with rheumatic diseases and finding unique clinical biomarkers, such as the anti-HMGCR antibody specificity.

Our laboratory pioneers innovations at the intersection of precision neurology, neuroengineering, artificial intelligence, and data science. We develop advanced neural-AI interfaces, autonomous wearable neurotechnologies, and immersive augmented and virtual reality platforms incorporating novel multimodal neuron-sensing technologies designed to personalize diagnostics, enhance therapeutic interventions, and optimize neurological rehabilitation. Leveraging computational neuroscience, AI, and applied data science, we generate robust digital biomarkers to monitor and treat neurologic diseases in real-time. Through interdisciplinary collaborations, we aim to transform clinical practice by providing precise, interactive, and personalized neurologic care that dramatically improves patient outcomes.

Lauren Jantzie, Ph.D. and colleagues across Johns Hopkins are identifying new biomarkers — measurable, physical signs — to help identify pediatric heart disease and brain injury. Along with Allen Everett, M.D., a leader in pediatric biomarker discovery, initially in sickle cell disease and subsequently in birth injury, congenital heart disease repair, ECMO, prematurity and pulmonary hypertension, Dr. Jantzie directs the Pediatric Proteome Center and integrates cutting edge molecular medicine with clinical innovation.

The goals of the Translational neurobiology Laboratory are to understand the pathogenesis and cell death pathways in neurodegenerative disorders to reveal potential therapeutic targets for pharmaceutical intervention; to investigate endogenous survival pathways and try to induce these pathways to restore full function or replace lost neurons; and to identify biomarkers to mark disease function or replace lost neurons; and to identify biomarkers to mark disease progression and evaluate therapeutics. Our research projects focus on models of Huntington's disease and Parkinson's disease. We use a combination of cell biology and transgenic animal models of these diseases.